Matrix metalloproteinase expression in the spondyloarthropathies

Current Opinion in Rheumatology

Volumn 18, Issue 4, 2006, Pages 364-368

  Zhu, Jian ^a   Yu, David Tak Yan ^b,c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c 35 36 Rehabilitation Center ^*  (United States)

Author keywords

Ankylosing spondylitis; Biomarker; Matrix metalloproteinase; MMP 3; Spondyloarthropathy; TNF blockers

Indexed keywords

ETANERCEPT; INFLIXIMAB; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; STROMELYSIN; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; CELL INFILTRATION; DISEASE ACTIVITY; DRUG EFFECT; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPONDYLOARTHROPATHY; SYNOVIAL FLUID; SYNOVIUM; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; HUMANS; IMMUNOGLOBULIN G; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASES; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHRITIS; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748049786     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000231904.04548.09     Document Type: Review

References (14)

1. Murphy G, Knauper V, Atkinson S, et al. Matrix metalloproteinases in arthritic disease. Arthritis Res 2002; 4 (Suppl 3):S39-S49.
2. Tchetverikov I, Lard LR, DeGroot J, et al. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003; 62:1094-1099.
3. Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol 2004; 31:238-242.
4. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839.
5. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62:817-824.
6. Spoorenberg A, van der Heijde D, de Klerk E, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999; 26:980-984.
7. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63:665-670.
8. Davis JC Jr, Van der Heijde DM, Dougados M, et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005; 32:1751-1754.
9. Yang C, Gu J, Rihl M, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004; 51:691-699.
10. Vandooren B, Kruithof E, Yu DT, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004; 50:2942-2953.
11. Jin L, Weisman M, Zhang G, et al. Lack of association of matrix metalloproteinase 3 (MMP3) genotypes with ankylosing spondylitis susceptibility and severity. Rheumatology (Oxford) 2005; 44:55-60.
12. Chen CH, Lin KC, Yu DT, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 2005; November 15 [Epub ahead of print]. This was the only study to calculate the sensitivity and specficity of serum MMP-3 levels in assessing disease activity in ankylosing spondylitis. It also compared results of two different cohorts.
13. Maksymowych WP, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29:959-965.
14. Maksymowych WP, Poole AR, Hiebert L, et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005; 32:1911-1917. This was the only study on the effect of etanercept on serum MMP levels.